Novel Imaging Modalities in MGUS, SMM, and MM

Phase 2, open-label, single-arm trial of sodium fluoride f-18 in multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS), sponsored by National Cancer Institute. Primary endpoints: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM at 60 days and Count of Participants With Positive DCE-MRI Imaging Results at 60 days. Started Oct 2010; status: completed.